FDA warns Texas medical spa for Botox dispensing discrepancies

The US Food and Drug Administration (FDA) has issued a warning letter to a medical spa company in Texas for violating the Drug Supply Chain Security Act (DSCSA) after finding the firm dispensed “significantly more” units of AbbVie’s Botox (onabotulinumtoxinA) than it purchased through legitimate channels.

In a warning letter dated 1 April, FDA inspectors cited Pure Indulgence Aesthetics for several DSCSA violations, including potentially selling products from a company or companies that were not authorized trading partners. Under the law, the company is only allowed to dispense medical products from an authorized trading partner, but inspectors found that it had dispensed more Botox than it had purchased from AbbVie, raising concerns that it had acquired additional products from an unauthorized manufacturer.

"Purchase records provided by both your firm and AbbVie (an authorized trading partner in accordance with section 581(2)(A) show your firm received [redacted] vials ([redacted] units) from AbbVie between December 18, 2024, and December 01, 2025," said FDA. "Patient treatment records, however, indicate that your firm administered product identified as 'Botox' to [redacted] patients between January 1, 2025, and December 1, 2025, with an estimated [redacted] units dispensed.

"This represents a discrepancy of [redacted] units (approximately [redacted] vials) between the amount of Botox indicated in your purchase records and the amount of product administered to patients," the agency added. "These descriptions of purchasing and dispensing align with what is indicated in the patient treatment records, but not with the records provided to FDA by both your firm and AbbVie documenting actual purchasing of Botox."

FDA also said the company failed to ensure that it dispensed products that included a product identifier. Inspectors found an unlabeled, clear vial containing a ring of white powder in the company's trash, which the company said it had no knowledge of. The agency conducted a laboratory analysis of the powder and found it to be botulinum neurotoxin type A, the active ingredient in Botox. However, inspectors noted that it was not an authentic AbbVie Botox vial.

"FDA investigators asked if you were able to provide a label or packaging for this product with required information, including a product identifier," said FDA. "In response, you denied any knowledge of the product and claimed not to recognize it.

"Therefore, you provided no evidence that the unlabeled, clear vial had been in a package or homogenous case that properly contained a required product identifier," the agency added.

While Pure Indulgence responded to FDA's Form 483 before the warning letter was issued, stating that it was taking corrective actions, the agency said it was insufficient because the response lacked sufficient details and documentation. The company also said it had conducted a retrospective review of its purchasing records and found no adverse events, but the agency said it was impossible to verify, as it had not received any documentation to support it, and raised concerns that the products it had already dispensed could not be traced in a recall.

Pure Indulgence said it has appointed a designated drug custodian with the sole authority for ordering and receiving prescription drugs, but FDA said the company again failed to provide any detailed documentation on who the custodian is. Furthermore, the agency said this was concerning, as the company has a history of obtaining unapproved products from foreign, unverified sources.

"At the inspection, FDA investigators were told of your firm’s practice of drawing product identified as Botox into 10-unit syringes and holding a supply of pre-filled syringes at the facility to be administered to patients," said FDA. "Your response states that 'the Facility prohibits storage or use of prescription drug products outside original manufacturer packaging.'

"However, without further detailed protocols in place, we are concerned that you will continue to remove the product from manufacturer vials prior to administration to patients," the agency added.

The FDA said Pure Indulgence hasn't taken sufficient remediation steps and asked the company to respond to its warning letter within 15 working days.

Warning letter